Compare CALC & CENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | CENN |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 9.9M |
| IPO Year | 2020 | 2017 |
| Metric | CALC | CENN |
|---|---|---|
| Price | $0.72 | $3.45 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 420.7K | 5.2K |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $18,080,161.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.07 |
| 52 Week High | $7.20 | $4.73 |
| Indicator | CALC | CENN |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 44.70 |
| Support Level | $0.52 | $3.40 |
| Resistance Level | $0.76 | $3.56 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 20.71 | 64.08 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, iChassis, Avantier, Teemak, Bison Motor, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the Europe, and also has a presence in America, Asia, and other regions.